Matthew Luchini
Stock Analyst at BMO Capital
(1.11)
# 3,432
Out of 4,829 analysts
50
Total ratings
32.14%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $7.86 | +281.68% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $4.74 | +3,908.44% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $17.52 | +293.84% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $4.13 | +2,418.16% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $1.58 | +3,381.01% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $6.52 | +1,449.08% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $575.63 | +9.45% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $300.76 | -58.77% | 2 | Nov 6, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | $1,120 | $3.29 | +33,942.55% | 11 | Nov 5, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $103.82 | -38.35% | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $28.30 | -50.53% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.49 | +3,926.85% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $120 → $164 | $7.87 | +1,988.95% | 5 | Mar 8, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $7.86
Upside: +281.68%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $4.74
Upside: +3,908.44%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $17.52
Upside: +293.84%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $4.13
Upside: +2,418.16%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $1.58
Upside: +3,381.01%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $6.52
Upside: +1,449.08%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $575.63
Upside: +9.45%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $300.76
Upside: -58.77%
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: $1,120
Current: $3.29
Upside: +33,942.55%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $103.82
Upside: -38.35%
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $28.30
Upside: -50.53%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.49
Upside: +3,926.85%
Mar 8, 2018
Maintains: Market Perform
Price Target: $120 → $164
Current: $7.87
Upside: +1,988.95%